Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
CONFERENCE HUB
Start Learning
Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face
A closeup of inflamed tissue healing over time, with a progression from active inflammation to a healthier state Inflammatory bowel disease IBD concept.
JOURNALS
Start Learning
Study finds comparable cardiovascular risk between JAKi and anti-TNFs in IBD
www.touchimmunology.com
JOURNALS
Start Learning
FDA approves bimekizumab for psoriatic arthritis, ankylosing spondylitis and axSpA
Bioinformatics immuno-oncology
JOURNALS
Start Learning
Shaping Immuno-oncology and Precision Medicine through Bioinformatics: Celebrating a pioneer in progress, Hassan Abushukair
touchEXPERT BRIEFING
Start Learning
UCB, making a difference in immunology
Sponsored content
JOURNALS
Start Learning
Breakthroughs in MASH: Highlights from EASL 2024
CONFERENCE HUB
Start Learning
The STENOVA Trial, a First-in-Class, First-in-Indication Study of AGMB-129 in Fibrostenotic Crohn’s Disease: Florian Rieder, DDW 2025
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025 severe allergic reactions, including anaphylaxis
JOURNALS
Start Learning
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025
touchEXPERT OPINIONS
Start Learning
Primary biliary cholangitis: Appraising the changing therapeutic landscape
CE/CME ACCREDITED
touchMDT
Start Learning
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
CE/CME ACCREDITED

to view Favourites, Keep Notes and Track CME Credits

Favourites
Advancing Rheumatology Through Innovation, Education and Patient-Centred Care: An Interview with Future Leader Dr Sham Santhanam
View
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
View
Key data on pain and prognosis: Clinical insights and implications
View
Efficacy and safety of izokibep: An investigational IL-17A inhibitor
View
A phase II trial of LEVI-04, a first-in-class, NT-3 inhibitor for the treatment of knee osteoarthritis: Philip Conaghan, WCO-IOF-ESCEO 2025
View
Breakthrough treatments for hereditary angioedema revealed at EAACI 2024
View
Novel anti-CD6 monoclonal antibody, itolizumab, showcases proof of concept in ulcerative colitis
View
New data support the efficacy and safety of cendakimab in eosinophilic oesophagitis
View
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
View
Optimizing Tumour Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis: Embracing Personalized Medicine
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup